Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL)

AbstractThe staging, prognostication, and treatment of ENKTL has evolved over the years with better understanding of the disease biology. There is significant heterogeneity in the treatment followed across the world. Literature from India have been few with small number of patients. We studied the outcomes and prognostic factors of patients with ENKTL treated between May 2010 and December 2021 at our center. A total of 78 patients diagnosed with ENKTL were treated at our center. L-asparaginase based chemotherapy was administered in 84% of the patients. Close to 2/3rd patients received SMILE chemotherapy. After a median follow-up of 30 months (18.5–41.4 months), the median relapse free survival and overall survival for the overall population was 45 months (12–118 months) and 45 months (14–118 months) respectively. By multivariate analysis, PINK score of 2–4, non-receipt of RT and non-achievement of CR were associated with poor survival.Keywords: Real world outcomes Extranodal NK T cell lymphomaL-asparaginase AcknowledgmentsThe authors acknowledge the help of Neha Sharma and Hitakshi in data capturingAuthors’ contributionsAkhil Rajendra, Manju Sengar, V.N.Avinash Bonda, Hasmukh Jain, Lingaraj Nayak and Jayashree Thorat designed and implemented the study; Akhil Rajendra, Manju Sengar, V.N.Avinash Bonda, Hasmukh Jain, Lingaraj Nayak, Jayashree Thorat and Bhausaheb Bagal contributed to acquisition of the data and documentation process; Akhil Rajendra, Manju Sengar, V.N.Avinash Bonda, Hasmukh Jain, Lingaraj Nayak, Jayashree Thorat, Epari Sridhar, Bhausaheb Bagal, Sangeeta Kakoti, Archie Aggarwal and Omkar Salvi planned and conducted data analysis; Akhil Rajendra, Manju Sengar, V.N.Avinash Bonda, Hasmukh Jain, Lingaraj Nayak, Jayashree Thorat and Epari Sridhar drafted the manuscript; Manju Sengar, Hasmukh Jain, Lingaraj Nayak, Epari Sridhar, Sumeet Gujral, Tanuja Seth, Siddharth Laskar, Archie Aggarwal and V. Rangarajan contributed to the critical revision of the manuscript; and all authors reviewed the manuscript and approved the final version for publication.Disclosure statementThe authors declare no competing financial interests.Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.